15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $616M | $447M | 83.7% | 20.0% | -$25M | $246M | $79M |
| 2024 | $329M | $23M | 88.3% | 12.7% | -$41M | $244M | $180M |
| 2023 | $234M | $13M | 94.0% | 8.8% | -$31M | $100M | $93M |
| 2022 | $3M | -$198M | 90.5% | -7839.0% | -$176M | $71M | $102M |
| 2021 | $7M | -$348M | 88.2% | -5154.3% | -$296M | $68M | $299M |
| 2014 | — | -$47M | — | — | — | — | $50M |
| 2013 | — | -$20M | — | — | — | — | $40M |
| 2013 | — | -$34M | — | — | -$11M | — | $50M |
| 2013 | — | -$29M | — | — | -$10M | — | $13M |
| 2013 | — | -$23M | — | — | -$7M | — | $15M |
| 2012 | — | -$18M | — | — | -$5M | — | $16M |
| 2012 | — | -$15M | — | — | -$4M | — | $17M |
| 2012 | — | -$13M | — | — | -$1M | — | $20M |
| 2012 | — | -$11M | — | — | — | — | $21M |
| 2011 | — | -$853074 | — | — | -$86577 | — | $10M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $205M | $20M | 83.6% | 17.0% | -$18M | $745M | $442M |
| Dec '25 | $193M | $23M | 80.2% | 26.2% | $20M | $246M | $79M |
| Sep '25 | $162M | $391M | 82.6% | 18.2% | -$23M | $245M | $74M |
| Jun '25 | $141M | $28M | 86.6% | 24.7% | $7M | $245M | $129M |
| Mar '25 | $121M | $5M | 87.1% | 7.1% | -$29M | $245M | $132M |
| Dec '24 | $108M | $23M | 85.8% | 27.7% | -$26M | $244M | $180M |
| Sep '24 | $84M | $4M | 88.9% | 14.8% | -$12M | $244M | $196M |
| Jun '24 | $73M | $7M | 88.7% | 12.0% | $6M | $103M | $83M |
| Mar '24 | $63M | -$11M | 91.4% | -14.6% | -$8M | $101M | $75M |
| Dec '23 | $44M | -$14M | 82.1% | -28.4% | -$13M | $100M | $93M |
| Sep '23 | $166M | $114M | 97.9% | 69.2% | — | $99M | $151M |
| Jun '23 | $16M | -$48M | 88.1% | -277.9% | — | $98M | $97M |
| Mar '23 | $8M | -$39M | 89.0% | -474.1% | — | $97M | $61M |
| Dec '22 | $80000 | -$53M | 96.3% | -65077.5% | -$24M | $71M | $102M |
| Sep '22 | $94000 | -$36M | 97.9% | -37194.7% | -$34M | $71M | $110M |
| Jun '22 | $594000 | -$41M | 0.0% | -6555.7% | -$49M | $69M | $147M |
| Mar '22 | $2M | -$69M | 0.0% | -3317.1% | -$69M | $67M | $186M |
| Dec '19 | — | -$40M | — | — | -$30M | $29M | $113M |
| Sep '19 | — | -$62M | — | — | -$33M | $29M | $45M |
| Jun '19 | — | -$36M | — | — | -$36M | $29M | $57M |
How the market has priced TGTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Tg Therapeutics, Inc.'s revenue has grown 209.8% per year. These are computed facts, not advice.
As of FY2025, Tg Therapeutics, Inc. reported $246M of total debt against $79M of cash; operating income covered interest expense 4.6×.
In FY2025, gross margin was 83.7%, operating margin 20.0%, and net margin 72.6%.
As of Jun '26, Tg Therapeutics, Inc. traded at a price-to-earnings ratio of about 18.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.